Longview Partners Guernsey LTD lessened its holdings in shares of Iqvia Holdings Inc (NYSE:IQV) by 1.5% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 9,539,945 shares of the medical research company’s stock after selling 144,020 shares during the period. Iqvia makes up approximately 6.1% of Longview Partners Guernsey LTD’s holdings, making the stock its 2nd largest position. Longview Partners Guernsey LTD’s holdings in Iqvia were worth $1,237,712,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Private Capital Group LLC raised its holdings in Iqvia by 177.0% in the 1st quarter. Private Capital Group LLC now owns 1,061 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 678 shares in the last quarter. Cutler Group LP grew its stake in shares of Iqvia by 173.3% in the 2nd quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock valued at $109,000 after purchasing an additional 2,600 shares during the period. Townsend & Associates Inc bought a new stake in shares of Iqvia in the 2nd quarter valued at approximately $117,000. Fort L.P. bought a new stake in shares of Iqvia in the 2nd quarter valued at approximately $118,000. Finally, Quad Cities Investment Group LLC bought a new stake in shares of Iqvia in the 2nd quarter valued at approximately $140,000. 90.40% of the stock is owned by institutional investors and hedge funds.

Several equities research analysts have recently weighed in on IQV shares. Royal Bank of Canada reiterated a “$110.25” rating and issued a $128.00 price objective on shares of Iqvia in a research note on Thursday, July 19th. ValuEngine upgraded Iqvia from a “hold” rating to a “buy” rating in a research report on Thursday, July 12th. Zacks Investment Research raised Iqvia from a “hold” rating to a “buy” rating and set a $111.00 price objective on the stock in a report on Wednesday, July 4th. SunTrust Banks upped their price objective on Iqvia to $140.00 and gave the stock a “buy” rating in a report on Wednesday, July 25th. Finally, Stifel Nicolaus upped their price objective on Iqvia from $128.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 25th. Five investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $126.95.

Shares of IQV stock traded down $0.54 during trading hours on Friday, reaching $127.88. The company had a trading volume of 43,719 shares, compared to its average volume of 1,103,295. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 1.40. The company has a market cap of $26.21 billion, a P/E ratio of 29.75, a price-to-earnings-growth ratio of 1.86 and a beta of 0.70. Iqvia Holdings Inc has a 1-year low of $91.57 and a 1-year high of $132.24.

Iqvia (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 24th. The medical research company reported $1.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.14 by $0.15. The business had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.50 billion. Iqvia had a return on equity of 13.51% and a net margin of 12.68%. The company’s revenue was up 9.0% compared to the same quarter last year. Research analysts anticipate that Iqvia Holdings Inc will post 5.13 earnings per share for the current fiscal year.

In other Iqvia news, Director John G. Danhakl sold 221,900 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $126.63, for a total transaction of $28,099,197.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John G. Danhakl sold 370,470 shares of the stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $124.83, for a total value of $46,245,770.10. The disclosure for this sale can be found here. In the last quarter, insiders have sold 978,777 shares of company stock valued at $121,566,089. Corporate insiders own 6.00% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Read More: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.